Mirum Pharmaceuticals, Inc. (MIRM) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Mirum Pharmaceuticals, Inc. (MIRM): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 49/100 — a percentile rank of Mirum Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.
| Market cap | $5.4B |
| P / S | 8.8× |
| EV / EBITDA | -7.3× |
| Gross margin | 81.7% |
| Operating margin | -134.9% |
| Net margin | -139.2% |
| Return on equity | 8253.8% |
| ROIC | -204.6% |
| Revenue growth | 44.0% |
| Debt / equity | -72.0× |
| Dividend yield | 0.0% |
Is Mirum Pharmaceuticals, Inc. overvalued? P/S looks fair vs its 5-year range.
Independent of the events above — derived from Mirum Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact